DDInter548 DDInter474
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosuria. Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents. Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April 2021.
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2A6
CYP2A6 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2A6
CYP2A6 {u} (Gene) is bound by {v} (Compound) Rifampicin
Rifampicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Dienestrol
Dienestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Canagliflozin {u} (Compound) resembles {v} (Compound) Dapagliflozin
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP2A6
CYP2A6 {u} (Gene) is bound by {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Diethylstilbestrol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) UGT2B7
UGT2B7 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Tamoxifen
Tamoxifen {u} (Compound) resembles {v} (Compound) Benzphetamine
Benzphetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Diethylstilbestrol {u} (Compound) resembles {v} (Compound) Ritodrine
Ritodrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Diethylstilbestrol (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Dapagliflozin (Compound)
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Diethylstilbestrol (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Rifampicin (Compound) and Rifampicin may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Diethylstilbestrol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound) and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Diethylstilbestrol (Compound) resembles Dienestrol (Compound) and Dienestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Diethylstilbestrol (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Diethylstilbestrol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with UGT2B7 (Gene) and UGT2B7 (Gene) is bound by Dapagliflozin (Compound)
Diethylstilbestrol (Compound) resembles Tamoxifen (Compound) and Tamoxifen (Compound) resembles Benzphetamine (Compound) and Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Diethylstilbestrol (Compound) resembles Ritodrine (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin